Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimatoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 8/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimatoprost SCHEMBL1286359 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12087441 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10015911 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL399000 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL24425 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10071021 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL13187412 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL20434484 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL22364345 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12076308 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128054-B2 | Aqueous pharmaceutical compositions of prostaglandins | FAMYGEN LIFE SCIENCES, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240156833-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF PROSTAGLANDINS | FAMYGEN LIFE SCIENCES, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11052152-B2 | Transdermal carrier | DYVE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210015925-A1 | TRANSDERMAL CARRIER | Ampersand Biopharmaceuticals, Inc. (US) | 2021-01-21 | — | — | US | disclosed |
| CN-107106569-B | Composition comprising a metal oxide and a metal oxide | 兴和株式会社 | 2020-07-28 | — | — | CN | disclosed |
| EP-3445745-B1 | PROCESS FOR THE PREPARATION OF BIMATOPROST | GENTEC S A (ES) | 2020-06-10 | — | — | EP | disclosed |
| US-10626080-B2 | Process for the preparation of bimatoprost | GENTEC, S.A. (ES) | 2020-04-21 | — | — | US | disclosed |
| US-10314780-B2 | Drippable opthalmic bimatoprost gel | MEDPROJECT PHARMA-ENTWICKLUNGS-UND VERTRIEBSGESELLSCHAFT MBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-20180215788-A1 | Compounds and Compositions for the Treatment of Ophthalmic Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| WO-2017182465-A1 | PROCESS FOR THE PREPARATION OF BIMATOPROST | GENTEC, S.A. (ES) | 2017-10-26 | — | — | WO | disclosed |
| EP-3235810-A1 | PROCESS FOR THE PREPARATION OF BIMATOPROST | Gentec, S.A. (ES) | 2017-10-25 | — | — | EP | disclosed |
| US-20160296532-A1 | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent | FORSIGHT VISION5, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160235851-A1 | Methods and formulations for transdermal administration | DYVE BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20140287988-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140287988-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | ASWATHANARAYANAPPA CHANDRASHEKAR (IN) | 2012-08-16 | — | — | US | disclosed |
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | ASWATHANARAYANAPPA CHANDRASHEKAR (IN) | 2012-08-16 | — | — | US | disclosed |
| WO-2011055377-A1 | A NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | BIOCON LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015925-A1 | TRANSDERMAL CARRIER | NACA, ETF1, SUCLG1 | PTGFR 331/4885ABCB11 515/4885AKR1C3 2383/4885 |
| US-10626080-B2 | Process for the preparation of bimatoprost | CYP2C19, CYP2C18, CCNT1 | PTGFR 787/4885ABCB11 490/4885AKR1C3 52/4885 |
| US-20140287988-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | LIPA, CYP27A1, HSD17B13 | PTGFR 4166/4885ABCB11 1556/4885AKR1C3 2135/4885 |
| US-11052152-B2 | Transdermal carrier | NACA, ETF1, SUCLG1 | PTGFR 331/4885ABCB11 515/4885AKR1C3 2383/4885 |
| US-10314780-B2 | Drippable opthalmic bimatoprost gel | CRYZ, PCNA, AVPR2 | PTGFR 125/4885ABCB11 861/4885AKR1C3 1433/4885 |
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | PTGER3, CBR3, PTGES3 | PTGFR 37/4885ABCB11 2869/4885AKR1C3 25/4885 |
| US-20160296532-A1 | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent | PDE6C, UACA, RAB5IF | PTGFR 2397/4885ABCB11 361/4885AKR1C3 2432/4885 |
| US-20240156833-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF PROSTAGLANDINS | PTGES3, PGF, PTGS1 | PTGFR 7/4885ABCB11 161/4885AKR1C3 806/4885 |
| US-20180215788-A1 | Compounds and Compositions for the Treatment of Ophthalmic Disorders | NPR1, NPR3, EDNRB | PTGFR 47/4885ABCB11 1700/4885AKR1C3 1540/4885 |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | LIPA, CYP27A1, HSD17B13 | PTGFR 4166/4885ABCB11 1556/4885AKR1C3 2135/4885 |
| US-12128054-B2 | Aqueous pharmaceutical compositions of prostaglandins | PTGES3, PGF, PTGS1 | PTGFR 7/4885ABCB11 161/4885AKR1C3 806/4885 |
| US-20160235851-A1 | Methods and formulations for transdermal administration | NACA, ETF1, KRT18 | PTGFR 377/4885ABCB11 1600/4885AKR1C3 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.